Placebo to match filgotinib
Sponsors
Gilead Sciences, Alfasigma S.p.A.
Conditions
Ankylosing SpondylitisFistulizing Crohn's DiseaseNoninfectious UveitisPsoriatic ArthritisRheumatoid ArthritisSmall Bowel Crohn's Disease
Phase 2
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
CompletedNCT03046056
Start: 2017-04-11End: 2020-07-20Updated: 2021-08-23
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
CompletedNCT03077412
Start: 2017-04-06End: 2021-02-17Updated: 2022-04-08
Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis
TerminatedNCT03207815
Start: 2017-07-26End: 2021-04-22Updated: 2022-01-21
Phase 3
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
CompletedNCT02873936
Start: 2016-07-27End: 2018-06-26Updated: 2021-05-13
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
CompletedNCT02886728
Start: 2016-08-08End: 2019-05-08Updated: 2021-06-01
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
CompletedNCT02889796
Start: 2016-08-30End: 2019-06-20Updated: 2021-06-09
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
CompletedNCT03025308
Start: 2017-02-28End: 2025-05-16Updated: 2026-07-27
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
TerminatedNCT04115748
Start: 2019-12-03End: 2021-05-11Updated: 2022-05-16
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
TerminatedNCT04115839
Start: 2019-11-13End: 2021-03-18Updated: 2022-03-18
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy
WithdrawnNCT04483687
Start: 2020-12-31End: 2024-09-30Updated: 2021-01-11
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy
WithdrawnNCT04483700
Start: 2020-12-31End: 2024-06-30Updated: 2021-01-11
Related Papers
27 more papers not shown